Journal Mobile Options
Table of Contents
Vol. 211, No. 3, 2005
Issue release date: 2005
Dermatology 2005;211:218–223

Nodular Scleroderma: Increased Expression of Connective Tissue Growth Factor

Yamamoto T. · Sawada Y. · Katayama I. · Nishioka K.
aDepartment of Dermatology, Tokyo Medical and Dental University, School of Medicine, Tokyo, and bOsaka University, Osaka, Japan

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Background: Nodular scleroderma is a fibrosing reaction, presenting well-defined, firm, raised nodules, which resembles keloid. Recent studies suggest that connective tissue growth factor (CTGF) is involved in the fibrotic process, and its expression is increased in many fibrosing diseases. Objective: In this study, we report 3 cases of nodular scleroderma, and the expression of CTGF is also investigated. Methods: Three patients who developed nodular scleroderma are described. Expression of CTGF protein and transcripts in nodular scleroderma was examined by immunohistochemistry and in situ hybridization. Results: Patients were 1 female and 2 males, and all cases were associated with diffuse systemic sclerosis. Nodular lesions were found on the chest (2 cases), back (1 case), upper arm (1 case) and nape (1 case). Histology of the nodular lesions showed thickened collagen bundles in the dermis. Results of immunohistochemistry showed that expression of CTGF was detected on the sclerotic fibroblasts in the lesions of nodular scleroderma, while it was not detected in fibroblasts in normal skin. In situ expression of CTGF transcripts was abundantly detected on the fibroblastic cells in nodular scleroderma. Conclusion: Our data showed increased expression of CTGF in the sclerotic fibroblasts of nodular scleroderma, suggesting that CTGF plays an important role in its pathogenesis.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Labandeira J, Leon-Mateos A, Suarez-Penaranda JM, Garea MT, Toribio J: What is nodular-keloidal scleroderma? Dermatology 2003;207:130–132.
  2. LeRoy EC, Smith EA, Kahaleh MB, Trojanowska M, Silver RM: A strategy for determining the pathogenesis of systemic sclerosis: Is transforming growth factor beta the answer? Arthritis Rheum 1989;32:817–825.
  3. Roberts AB, Sporn MB: The transforming growth factor βs; in Sporn MB, Roberts AB (eds): Handbook of Experimental Pharmacology: Peptide Growth Factors and Their Receptors. New York, Springer, 1990, vol 95, pp 419–472.
  4. Bradham DM, Igarashi A, Potter RL, Grotendorst GR: Connective tissue growth factor: A cystein-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10. J Cell Biol 1991;114:1285–1294.
  5. Igarashi A, Okochi H, Bradham DM, Grotendorst GR: Regulation of connective tissue growth factor gene expression in human skin fibroblasts and during wound repair. Mol Biol Cell 1993;4:637–645.
  6. Frazier K, Williams S, Kothapalli D, Klapper H, Grotendorst GR: Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor. J Invest Dermatol 1996;107:404–411.
  7. Grotendorst GR, Okochi H, Hayashi N: A novel transforming growth factor beta response element controls the expression of connective tissue growth factor gene. Cell Growth Differ 1996;7:469–480.
  8. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Grotendorst GR, Takehara K: Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis. J Invest Dermatol 1995;105:280–284.
  9. Igarashi A, Nashiro K, Kikuchi K, Sato S, Ihn H, Fujimoto M, Grotendorst GR, Takehara K: Connective tissue growth factor gene expression in tissue sections from localized scleroderma, keloid, and other fibrotic skin disorders. J Invest Dermatol 1995;106:729–733.
  10. Scharffetter K, Lankat-Buttgereit B, Krieg T: Localization of collagen mRNA in normal and scleroderma skin by in-situ hybridization. Eur J Clin Invest 1988;18:9–17.
  11. Burge SM, Mortimer PS, Ryan TJ: Pseudokeloidal scleroderma. Br J Dermatol 1985;113(suppl 29):99.

    External Resources

  12. James WD, Berger TG, Butler DF, Tuffanelli DL: Nodular (keloidal) scleroderma. J Am Acad Dermatol 1984;11:1111–1114.
  13. Sasaki T, Denpo K, Ono H, Nakajima H: Nodular scleroderma in systemic sclerosis under D-penicillamine therapy. J Dermatol 1992;19:968–971.
  14. Perez-Wilson J, Pujol RM, Alejo M, Geli C, de Moragas J: Nodular (keloidal) scleroderma. Int J Dermatol 1992;31:422–424.
  15. Yamamoto T, Furuse Y, Katayama I, Nishioka K: Nodular scleroderma in a worker using a silica-containing abrasive. J Dermatol 1994;21:751–754.
  16. Krell JM, Solomon AR, Glavey CM, Lawley TJ: Nodular scleroderma. J Am Acad Dermatol 1995;32:343–345.
  17. Mizutani H, Taniguchi H, Sakakura T, Shimizu M: Nodular scleroderma: Focally increased tenascin expression differing from that in the surrounding scleroderma skin. J Dermatol 1995;22:267–271.
  18. Wollina U, Looks A, Lange D: Extracorporeal photochemotherapy in nodular scleroderma. Br J Dermatol 1998;139:559–560.
  19. Ling TC, Herrick AL, Andrew SM, Brammah T, Griffiths CEM: Keloidal scleroderma. Clin Exp Dermatol 2003;28:171–173.
  20. Barzilai A, Lyakhovitsky A, Horowitz A, Trau H: Keloid-like scleroderma. Am J Dermatopathol 2003;25:327–330.
  21. Cantwell AR, Rowel L, Kelso DW: Nodular scleroderma and pleomorphic acid-fast bacteria. Arch Dermatol 1980;116:1283–1290.
  22. Bettley FR, Seville RH: Nodular scleroderma. Proc R Soc Med 1951;44:573–575.
  23. Akintewe TA, Alabi GO: Scleroderma presenting with multiple keloids. Br Med J 1985;291:448–449.
  24. Micalizzi C, Parodi A, Rebora A: Morphoea with nodular lesions. Br J Dermatol 1994;131:298–300.
  25. Hsu S, Lee M-W C, Carlton S, Kramer EM: Nodular morphea in a linear pattern. Int J Dermatol 1999;38:529–530.
  26. Kubo M, Tamaki T, Fujimoto M, Kikuchi K, Tamaki K: Keloidlike morphea. Acta Derm Venereol (Stockh) 1997;77:90–91.
  27. Cannick L III, Douglas G, Crater S, Silver R: Nodular scleroderma: Case report and literature review. J Rheumatol 2003;30:2500–2502.
  28. Labandeira J, Leon-Mateos A, Suarez-Penaranda JM, Garea MT, Toribio J: Polymorphic fibrosing reaction mimicking keloidal scleroderma but without associated classic scleroderma. Dermatology 2003;207:204–205.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50